第十一批国采,超500药企拟角逐75个临床大品种,谁能脱颖而出?日前,一份关于《第十一批国家组织药品集中采购拟采购药品清单》意见的函在业内流出,意味着酝酿许久的新批次国采启动在即。据悉,本次国采拟纳入75个品种,其中注射剂延续此前趋势,数量最多,达到34个;口服常释剂型数量次之,也多达32个;纳入部分特殊剂型,包括丙卡特罗和福莫特罗两个吸入剂,帕利哌酮缓释控释剂型和洛索洛芬贴剂。从企业层面来看,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.